Advertisement

Surgery Today

, Volume 47, Issue 9, pp 1104–1110 | Cite as

Significance of lymph node metastasis in pancreatic neuroendocrine tumor

  • Katsunobu Taki
  • Daisuke Hashimoto
  • Shigeki Nakagawa
  • Nobuyuki Ozaki
  • Shinjiro Tomiyasu
  • Masaki Ohmuraya
  • Kota Arima
  • Takayoshi Kaida
  • Takaaki Higashi
  • Keita Sakamoto
  • Kazuya Sakata
  • Hirohisa Okabe
  • Hidetoshi Nitta
  • Hiromitsu Hayashi
  • Akira Chikamoto
  • Toru Beppu
  • Hiroshi Takamori
  • Masahiko Hirota
  • Hideo BabaEmail author
Original Article

Abstract

Purpose

Pancreatic neuroendocrine tumor (PNET) is relatively rare and has a generally better prognosis than does pancreatic cancer. However, as its prognosis in patients with lymph node metastasis (LNM) is unclear, lymph node dissection for PNET is controversial. Our study aimed to clarify the significance of LNM in PNET.

Methods

We retrospectively examined 83 PNET patients who underwent pancreatic resections with lymph node dissection at Kumamoto University Hospital, Saiseikai Kumamoto Hospital, and Kumamoto Regional Medical Center from April 2001 to December 2014. Their clinicopathological parameters were analyzed by the absence or presence of LNM, and with regard to the disease-free survival (DFS) and overall survival (OS). A predictive score of LNM was also made using the age, tumor size, primary tumor location, and tumor function.

Results

Although the 5-year OS was 74.8% for LNM+ and 94.6% for LNM (P = 0.002), LNM was not an independent risk factor for the OS in a multivariate analysis. However, tumors larger than 1.8 cm were found to be an independent prognostic factor, and the cut-off value for the predictive score was 1.69.

Conclusions

Although LNM was not an independent prognostic factor, lymph node dissection is recommended for patients whose predictive score is larger than 1.69.

Keywords

Pancreas Neuroendocrine tumor Pancreatic neuroendocrine tumor Lymph node metastasis Prognosis 

Notes

Acknowledgements

The authors declare no conflicts of interest. No funding was received for this study.

References

  1. 1.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012;41:840–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014;208:775–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yoo YJ, Yang SJ, Hwang HK, Kang CM, Kim H, Lee WJ. Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas. Medicine (Baltimore). 2015;94:e1404.CrossRefGoogle Scholar
  9. 9.
    Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526–31.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47.CrossRefPubMedGoogle Scholar
  11. 11.
    Kim MJ, Choi DW, Choi SH, Heo JS, Park HJ, Choi KK, et al. Surgical strategies for non-functioning pancreatic neuroendocrine tumours. Br J Surg. 2012;99:1562–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20:2815–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol. 2014;21:2882–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, et al. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. J Gastrointest Surg. 2016;20:1966–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl). 2015;128:3335–44.CrossRefGoogle Scholar
  16. 16.
    Postlewait LM, Ethun CG, Baptiste GG, Le N, McInnis MR, Cardona K, et al. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. J Surg Oncol. 2016;114:440–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845–51. (discussion 52-3).CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford). 2009;11:422–8.CrossRefGoogle Scholar
  20. 20.
    Brunner SM, Weber F, Werner JM, Agha A, Farkas SA, Schlitt HJ, et al. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg. 2015;15:49.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fischer L, Bergmann F, Schimmack S, Hinz U, Priess S, Muller-Stich BP, et al. Outcome of surgery for pancreatic neuroendocrine neoplasms. Br J Surg. 2014;101:1405–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol. 2014;21:3515–21.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg. 2006;141:765–9. (discussion 9–70).CrossRefPubMedGoogle Scholar
  24. 24.
    Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.CrossRefPubMedGoogle Scholar
  25. 25.
    Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95:627–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Arima K, Hashimoto D, Okabe H, Inoue R, Kaida T, Higashi T, et al. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Surg Today. 2016;46:792–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.CrossRefPubMedGoogle Scholar
  28. 28.
    Mizuguchi T, Torigoe T, Satomi F, Shima H, Kutomi G, Ota S, et al. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Surg Today. 2016;46:139–48.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2017

Authors and Affiliations

  • Katsunobu Taki
    • 1
  • Daisuke Hashimoto
    • 1
  • Shigeki Nakagawa
    • 1
  • Nobuyuki Ozaki
    • 2
  • Shinjiro Tomiyasu
    • 3
  • Masaki Ohmuraya
    • 4
  • Kota Arima
    • 1
  • Takayoshi Kaida
    • 1
  • Takaaki Higashi
    • 1
  • Keita Sakamoto
    • 1
  • Kazuya Sakata
    • 1
  • Hirohisa Okabe
    • 1
  • Hidetoshi Nitta
    • 1
  • Hiromitsu Hayashi
    • 1
  • Akira Chikamoto
    • 1
  • Toru Beppu
    • 1
  • Hiroshi Takamori
    • 2
  • Masahiko Hirota
    • 3
  • Hideo Baba
    • 1
    Email author
  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  2. 2.Department of SurgerySaiseikai Kumamoto HospitalKumamotoJapan
  3. 3.Department of SurgeryKumamoto Regional Medical CenterKumamotoJapan
  4. 4.Institute of Resources Development and AnalysisKumamoto UniversityKumamotoJapan

Personalised recommendations